Introduction: To investigate the clinical effects
INTRODUCTION
Current international guidelines promote the use of insulin treatment in patients with type 2 diabetes (T2D) when lifestyle changes and oral hypoglycemic agents (OHA) fail to achieve adequate glycemic control [1] [2] [3] . It is usually recommended to start with a basal insulin at bedtime, i.e., the medium long-acting neutral protamine Hagedorn (NPH) or a long-acting insulin analog [insulin glargine (IG) or insulin detemir (ID)], but premixed insulin (PM), usually administered twice daily, is a frequently used alternative [4] . IG and ID are advocated particularly in patients experiencing nocturnal hypoglycemia [1, 2] , while the latter has been shown to require higher doses to achieve similar metabolic effects [5] .
The clinical effects of these different insulin treatment regimens have been evaluated in randomized clinical trials (RCT) and subsequent meta-analyses, which together constitute the foundation of the treatment guidelines. Usually only RCTs are included in meta-analyses [6, 7] . Thus, the effects in clinical practice have generally not been described, although there are a small number of retrospective cohort studies that have evaluated different insulin therapies clinically [8] [9] [10] [11] . One study compared different insulin-treatments in 4 showed greatest weight gain and highest insulin dose, but showed superior persistence.
The authors initiated this register-based project to study the effects of four insulin regimens in 5,077 insulin-naïve patients with T2D, resident in the geographical region of Western Sweden (Region Västra Götaland), the clinical effects, such as changes in HbA1c and body mass index (BMI), insulin dose, and frequencies of hypoglycemia.
Another aim of the project was to investigate health care utilization and costs, but these results will be presented in a subsequent report.
METHODS
This is a retrospective cohort study based on information retrieved from four national health registers: the Swedish National Diabetes Register (NDR), the Prescribed Drug Register, the Cause Mono-S method.
Statistical Methods
Baseline characteristics are presented as means ± 1 standard deviation (SD) or medians for continuous variables and frequencies for categorical variables with crude significance levels for differences between the groups, when analyzed using ANOVA or v 2 test (Table 1) 
RESULTS
In total, 5,077 insulin-naïve patients with T2D were included in the study. The majority were initiated on NPH (49%) or PM (34%), while 13% and 3% were initiated on IG and ID,
respectively. There were overall significant differences in clinical characteristics between the groups ( Table 2 ). The proportion of patients censored due to any cause was lowest in IG, mostly due to less treatment switches (3.1%) compared to NPH (6.9%), ID (8.2%) and PM (4.6%). There were significant differences in censoring due to death, with the highest proportion seen in PM (4.5%) and the lowest proportion seen in ID (0.6%). However, this analysis was not adjusted for differences in clinical characteristics between the groups. Table 3 describes mean ± SD for HbA1c and BMI at baseline, end of follow-up, as well as unadjusted changes in HbA1c and BMI during follow-up in the different groups. HbA1c levels at baseline ranged between 67 ± 16 mmol/mol (PM) and 68 ± 17 mmol/mol (NPH) with no statistically significant differences between the groups. Change in HbA1c also did not differ significantly between the groups, ranging between -7 ± 17 mmol/mol (IG) and -9 ± 18 mmol/mol (NPH). The non-significant differences in change of HbA1c remained when IG, ID or PM was compared with NPH as reference, adjusted for covariates. There were There were significant differences in insulin doses between the groups (Table 7) . Among patients receiving insulin in monotherapy, the weight-adjusted doses were highest in PM and ID. However, when doses of mealtime insulins were taken into account, only ID required higher doses. In patients treated with insulin in combination with OHA, both ID and PM required higher weight-adjusted doses even when mealtime insulin use was taken into account. NPH and IG required similar weightadjusted doses in patients receiving insulin in monotherapy as well as in patients with insulin in combination with OHA. Covariance-adjusted comparisons of weight-adjusted daily insulin doses with IG, ID or PM and NPH as reference showed that patients treated with ID and PM required 59% and 25% higher doses, p\0.0001 (Table 6 ). The required insulin doses did not differ significantly between IG and NPH.
Hypoglycemia requiring admission to a hospital occurred infrequently. The total number of patients experiencing severe hypoglycemia was 26, with the largest Patients treated with ID and PM required 59% The achieved HbA1c changes in the present study were smaller than seen in previous observational studies [10, 12, 17] and RCTs [5, 18, 19] . The insulin doses in the present study were in general similar or only slightly lower than in these previous studies, and cannot fully explain the modest HbA1c change.
However, patient characteristics at inclusion differed significantly between these studies. For example, HbA1c levels at the time of insulin initiation were considerably lower in the present study than in previous studies based on data from routine clinical care [10, 12, 17] . Interestingly, a meta-analysis including 38,803 patients from 87
RCTs found a quite strong positive relationship between baseline Hba1c and the magnitude of HbA1c change [20] . Similar relationship has been reported from observational data [12] . Thus, the relatively low HbA1c levels at baseline and possibly fear of hypoglycemia might be explanations to the modest HbA1c reductions seen in the present study.
The present results are fairly consistent with previous findings. The Treating to Target in Type 2 Diabetes (4-T) Study evaluated the efficacy of basal insulin, prandial insulin, or biphasic (premixed) insulin in insulin-naïve patients with T2D [18] .
After 1 year of follow-up, PM and prandial insulin were superior to basal insulin in lowering HbA1c, but at the cost of more frequent hypoglycemic episodes and more weight gain [18] . However, at 3 years of follow-up the insulin regimens were equally effective in controlling HbA1c, but the lower rate of hypoglycemia in the basal insulin group remained [21] . A recently published propensity score-matched observational study also found basal insulin and premixed insulin to be equally effective in lowering HbA1c, but with less weight gain and a lower rate of hypoglycemia with basal insulin [17] . These studies, however, did not distinguish between different types of basal insulin. Consistent with results from metaanalyses [6, 7, 22, 23] and RCTs [5] , the present study did not show significant differences in achieved HbA1c reductions between NPH, IG or ID, but with higher required doses for ID. Thus, the finding of a slightly greater HbA1c reduction with IG reported in a study based on data from a primary care register in the United Kingdom was not confirmed [12] .
The difficulties of obtaining valid information on hypoglycemia through registers have been recognized in previous observational studies. In the present study, only 26 patients with hypoglycemia were reported. This could be a substantial underestimation of the total number of hypoglycemia. However, the present data support a higher frequency in patients treated with PM [18] and possibly NPH, and also RCTs demonstrating less hypoglycemic episodes in patients treated with IG and ID compared to NPH [6, 24] .
The present study has several strengths. The data were collected from the NDR database with a currently estimated coverage of more than 90% of all patients in hospital outpatient clinics and almost 80% of all patients in primary care 
